Skip to main content
AIM ImmunoTech Inc. logo

AIM ImmunoTech Inc. — Investor Relations & Filings

Ticker · AIM ISIN · US42366C3016 US Professional, scientific and technical activities
Open in API
Filings indexed 1,092 across all filing types
Latest filing 2024-12-05 Proxy Solicitation & In…
Country US United States of America
Listing US AIM

About AIM ImmunoTech Inc.

https://aimimmuno.com/

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics for various diseases. The company's primary areas of focus include oncology, immune disorders, and viral diseases. Its lead drug candidate is Ampligen® (rintatolimod), a proprietary immuno-modulator with broad-spectrum activity demonstrated in pre-clinical testing. Ampligen® is being evaluated in multiple clinical studies for a range of debilitating and life-threatening conditions.

Recent filings

Filing Released Lang Actions
Proxy Solicitation & Information Statement 2024
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a definitive proxy statement or additional materials related to a proxy solicitation for the company's 2024 Annual Meeting of Stockholders. It includes detailed information about board nominees, proxy advisory firm recommendations, and solicitation of shareholder votes. The text explicitly references the proxy statement and proxy card, and urges shareholders to vote. There is no financial data or earnings information, nor is it an announcement of a report publication. The document is not a full annual report, earnings release, or management discussion. It is focused on proxy solicitation and voting information, which corresponds to the Remuneration Information or Proxy Solicitation & Information Statement categories. Since it is a Schedule 14A filing with detailed proxy materials and solicitation information, the correct classification is Proxy Solicitation & Information Statement (PSI).
2024-12-05 English
Regulatory Filings 2024
Regulatory Filings
2024-12-05 English
Proxy Solicitation & Information Statement 2024
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a Proxy Statement pursuant to Section 14(a) of the Securities Exchange Act of 1934. It references the Definitive Proxy Statement and additional materials related to the solicitation of proxies for the 2024 Annual Meeting of Stockholders. The text emphasizes the importance of reading the Definitive Proxy Statement and related proxy materials. There is no actual financial data or report content, but rather materials related to proxy solicitation and shareholder voting information. This matches the definition of Proxy Solicitation & Information Statement (PSI). The document length is 4700 characters, which is consistent with a proxy statement filing rather than a full annual report or other financial report. Therefore, the correct classification is PSI with high confidence.
2024-12-04 English
Capital/Financing Update 2024
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to the resale of shares of common stock by a selling stockholder. It is a registration statement component, describing the offering of shares, the selling stockholder, plan of distribution, and related legal and financial information. The document is not a financial report, earnings release, or management discussion, but rather a capital markets filing related to securities offering and resale. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes through a resale registration statement.
2024-12-04 English
Director's Dealing 2024
Director's Dealing
2024-12-04 English
Director's Dealing 2024
Director's Dealing
2024-12-03 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.